Metabolic Dysfunction-associated Steatotic Liver Disease
The central purpose of the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG (formerly the NAFLD SIG) is to provide a forum to share ideas, foster collaboration and brainstorm together as an academy of basic and translational investigators. Our mission is to study the pathogenesis, diagnosis, natural history and development of therapeutics for metabolic dysfunction-associated steatotic Liver disease. The MASLD SIG sponsors programs at the AASLD Annual Meeting, identifies emerging topics in MASLD, and supports the educational mission of AASLD. policy.
SIG Leadership
- Chairs
- Mazen Noureddin, MD, MHSc
- Alina M. Allen, MD
- Associate Lead
- Jessica Bartholomew, NP
- Communication Lead
- Pinelopi Manousou
- Education Lead
- Robert J. Fontana, MD, FAASLD
- Trainee Lead
- Maria Mironova, MD
- SIG Steering Committee Members
- Grace L. Guo, FAASLD
- Yaron Rotman, MD, MSc, FAASLD
- Advanced Transplant/Hepatology Awardee
- Stefani Tica, MD, MPH
- Staff Liaisons
- Akuender Dot, MPH
- Julie Hoffman, MBA
- Emerging Liver Advanced Practice Provider Program Awardee
- Kristy Kiermaier, NP